Kidney Week

Abstract: SA-PO045

Safety and Efficiency Evaluation of Carbon Dioxide Removal in Combination with Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy: Baseline Characteristics of the multiECCO2R Study

Session Information

• AKI: Clinical, Outcomes, and Trials - Management
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 102 AKI: Clinical, Outcomes, and Trials

Authors

• Wammi, Anna Patrizia, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany

Anna Patrizia Wammi, MSc

• Kluge, Stefan, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany

Stefan Kluge, DrMed

• Jarczak, Dominik, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany

Dominik Jarczak, DrMed

• Willam, Carsten, Universitatsklinikum Erlangen, Erlangen, Bayern, Germany

Carsten Willam, MD

• Blaas, Stefan Helmut, Klinik Donaustauf, Donaustauf, Bayern, Germany

Stefan Helmut Blaas, MD

• Ottillinger, Bertram, Ottillinger Life Sciences, Brunnthal, Bayern, Germany

Bertram Ottillinger, DrMed

• Korolev, Natalia, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany

Natalia Korolev

• Braun, Jennifer, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany

Jennifer Braun, PhD

• Stauss-Grabo, Manuela, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany

Manuela Stauss-Grabo, PhD

Background

Extracorporeal carbon dioxide removal (ECCO₂R) was introduced to reduce the level of blood CO₂ in patients with acute respiratory distress syndrome (ARDS) and to limit the risk of ventilator-induced lung injury. The use of CO₂ removal gas exchangers could allow non-invasive ventilation techniques or the adoption of protective invasive mechanical ventilation reducing pulmonary stress. The CO₂ blood gas exchanger multiECCO2R with a surface of 1,35 m² can be integrated into a CRRT platform downstream of the dialyzer, allowing simultaneous treatment of adult patients with ARDS and acute kidney injury.

Methods

The open, interventional post-market clinical follow-up study plans to enroll 40 patients overall in Germany, it is currently in the recruitment phase. Patients with combined renal failure and hypercapnia due to acute lung failure in COVID-19 and other forms of respiratory insufficiency (e.g. ARDS) are being recruited and will be treated on the multiFiltrate MFT/MFT PRO (Fresenius Medical Care) with the multiECCO₂R gas exchanger (EUROSETS) for up to 72 hours.

Results

17 patients (12 males) with a mean age of 66.8±11.3 years and a baseline paCO2 value of 59.2±8.3 mmHg treated with best possible protective ventilation setting have been recruited. The leading cause for renal disease was sepsis (42.1%), and the leading cause for lung disease was pneumonia (50%). All included patients were treated in a CVVHD setting, with a mean blood flow of 186.5±75.3 ml/h and anticoagulation with heparin (47.1%) or citrate (52.9%).

Conclusion

The multiECCO₂R study will evaluate safety and efficiency of CO₂ removal in combination with CRRT treatment. Trial results are planned to be reported in 2025.

Funding

• Commercial Support – Fresenius Medical Care Deutschland GmbH